NasdaqGS - Nasdaq Real Time Price USD

Jazz Pharmaceuticals plc (JAZZ)

Compare
121.41
+1.18
+(0.98%)
At close: 4:00:02 PM EST
122.45
+1.04
+(0.86%)
After hours: 4:24:58 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
3,992,712.00
3,834,204.00
3,659,374.00
3,094,238.00
2,363,567.00
Cost of Revenue
424,243.00
435,577.00
540,517.00
440,760.00
148,917.00
Gross Profit
3,568,469.00
3,398,627.00
3,118,857.00
2,653,478.00
2,214,650.00
Operating Expense
2,892,112.00
2,801,047.00
2,606,589.00
2,483,200.00
1,449,188.00
Operating Income
676,357.00
597,580.00
512,268.00
170,278.00
765,462.00
Net Non Operating Interest Income Expense
-257,165.00
-289,438.00
-288,242.00
-278,766.00
-99,707.00
Other Income Expense
-20,534.00
-10,213.00
-596,810.00
-4,350.00
-390,660.00
Pretax Income
398,658.00
297,929.00
-372,784.00
-112,838.00
275,095.00
Tax Provision
-66,606.00
-119,912.00
-158,645.00
216,116.00
33,517.00
Earnings from Equity Interest Net of Tax
-2,105.00
-3,009.00
-9,921.00
-714.00
-2,962.00
Net Income Common Stockholders
463,159.00
414,832.00
-224,060.00
-329,668.00
238,616.00
Average Dilution Earnings
15,686.00
24,876.00
--
--
--
Diluted NI Available to Com Stockholders
478,845.00
439,708.00
-224,060.00
-329,668.00
238,616.00
Basic EPS
7.43
6.55
-3.58
-5.52
4.28
Diluted EPS
7.06
6.10
-3.58
-5.52
4.22
Basic Average Shares
62,348.25
63,291.00
62,539.00
59,694.00
55,712.00
Diluted Average Shares
68,049.75
72,066.00
62,539.00
59,694.00
56,517.00
Total Operating Income as Reported
648,357.00
578,580.00
-65,528.00
170,278.00
378,073.00
Total Expenses
3,316,355.00
3,236,624.00
3,147,106.00
2,923,960.00
1,598,105.00
Net Income from Continuing & Discontinued Operation
463,159.00
414,832.00
-224,060.00
-329,668.00
238,616.00
Normalized Income
479,380.86
422,900.27
247,419.90
-326,492.50
581,615.48
Interest Expense
257,165.00
289,438.00
288,242.00
278,766.00
99,707.00
Net Interest Income
-257,165.00
-289,438.00
-288,242.00
-278,766.00
-99,707.00
EBIT
655,823.00
587,367.00
-84,542.00
165,928.00
374,802.00
EBITDA
1,306,674.00
1,226,063.00
544,929.00
718,411.00
653,055.00
Reconciled Cost of Revenue
393,355.00
405,165.00
510,215.00
414,046.00
130,244.00
Reconciled Depreciation
650,851.00
638,696.00
629,471.00
552,483.00
278,253.00
Net Income from Continuing Operation Net Minority Interest
463,159.00
414,832.00
-224,060.00
-329,668.00
238,616.00
Total Unusual Items Excluding Goodwill
-20,534.00
-10,213.00
-596,810.00
-4,350.00
-390,660.00
Total Unusual Items
-20,534.00
-10,213.00
-596,810.00
-4,350.00
-390,660.00
Normalized EBITDA
1,327,208.00
1,236,276.00
1,141,739.00
722,761.00
1,043,715.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-4,312.14
-2,144.73
-125,330.10
-1,174.50
-47,660.52
12/31/2020 - 6/1/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IONS Ionis Pharmaceuticals, Inc.
33.46
-1.88%
 
BMRN BioMarin Pharmaceutical Inc.
67.38
-1.46%
 
INCY Incyte Corporation
70.54
-3.54%
 
ALNY Alnylam Pharmaceuticals, Inc.
237.98
-1.07%
 
BHVN Biohaven Ltd.
36.72
-6.25%
 
UTHR United Therapeutics Corporation
364.97
-0.45%
 
ASND Ascendis Pharma A/S
129.19
-3.90%
 
EXEL Exelixis, Inc.
36.02
+4.41%
 
RARE Ultragenyx Pharmaceutical Inc.
42.07
-3.62%
 
CRNX Crinetics Pharmaceuticals, Inc.
40.59
-16.31%